Found: 17
Select item for more details and to access through your institution.
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 1, p. 62, doi. 10.1007/s10637-017-0480-x
- By:
- Publication type:
- Article
Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH‐EP1 study.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 4, p. 645, doi. 10.1002/ajh.26835
- By:
- Publication type:
- Article
Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B‐cell lymphoma: Results of LNH‐EP1 study.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 10, p. E376, doi. 10.1002/ajh.26280
- By:
- Publication type:
- Article
Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin's lymphoma not eligible for intensive chemotherapy.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 4, p. 574, doi. 10.1111/ejh.13589
- By:
- Publication type:
- Article
High‐dose cyclophosphamide for hard‐to‐treat patients with relapsed or refractory B‐cell non‐Hodgkin's lymphoma, a phase II result.
- Published in:
- European Journal of Haematology, 2020, v. 104, n. 4, p. 281, doi. 10.1111/ejh.13369
- By:
- Publication type:
- Article
Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.
- Published in:
- 2021
- By:
- Publication type:
- journal article
The Impact of Risk-adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplant.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S306, doi. 10.1016/j.clml.2018.07.267
- By:
- Publication type:
- Article
Allogeneic Hematopoietic Stem Cell Transplant in Elderly Patients Using Reduce Intensity Conditioning Regimen: A Single Centre Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S388, doi. 10.1016/j.clml.2017.07.239
- By:
- Publication type:
- Article
<sup>18</sup>F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor.
- Published in:
- Journal of Nuclear Medicine, 2018, v. 59, n. 1, p. 15, doi. 10.2967/jnumed.117.193011
- By:
- Publication type:
- Article
When monoclonal gammopathy‐associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes.
- Published in:
- EJHaem, 2023, v. 4, n. 3, p. 823, doi. 10.1002/jha2.713
- By:
- Publication type:
- Article
Repeated courses of low‐dose 2 × 2 Gy radiation therapy in patients with indolent B‐cell non‐Hodgkin lymphomas.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 11, p. 3725, doi. 10.1002/cam4.2796
- By:
- Publication type:
- Article
Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2017, v. 44, n. 12, p. 2018, doi. 10.1007/s00259-017-3758-5
- By:
- Publication type:
- Article
Reduced frequency of cytotoxic CD56<sup>dim</sup> CD16<sup>+</sup> NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 1, p. 13, doi. 10.1007/s00262-021-02956-x
- By:
- Publication type:
- Article
Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study.
- Published in:
- Cancers, 2023, v. 15, n. 5, p. 1508, doi. 10.3390/cancers15051508
- By:
- Publication type:
- Article
CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy.
- Published in:
- Cancers, 2021, v. 13, n. 21, p. 5487, doi. 10.3390/cancers13215487
- By:
- Publication type:
- Article
Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method.
- Published in:
- Cancers, 2019, v. 11, n. 10, p. 1611, doi. 10.3390/cancers11101611
- By:
- Publication type:
- Article